DEERFIELD, Ill., January 9, 2012 - Baxter International Inc. (NYSE:BAX) announced today that Jean-Luc Butel has been appointed corporate vice president and president, international, reporting to Robert L. Parkinson, Jr., chairman and chief executive officer. He will assume his new role on February 20, 2012.
Butel, 55, will be responsible for leading the company's international operations. Most recently, Butel was Executive Vice President and Group President, International, at Medtronic.
"Geographic expansion continues to be a key growth driver for Baxter. Our global presence and the strength of our country and regional organizations position us to meet the ever increasing demand for healthcare worldwide, particularly for the medically necessary products that we provide," said Robert L. Parkinson, Jr., chairman and chief executive officer. "Jean-Luc brings significant international expertise to Baxter, and he will be a tremendous asset to the company in his new role leading our international business."
Butel served in a variety of senior management positions at Medtronic since 2003, including leading the company's international business operations and the Asia Pacific region. Prior to Medtronic, he spent 13 years with Johnson & Johnson in roles of increasing responsibility, and eight years with Becton Dickinson in leadership roles, including general manager of the Microbiology business in Japan, president of Japan and president of Worldwide Consumer Healthcare.
Butel received his B.A. in international affairs from George Washington University, and his M.B.A. in international business from the American School of International Management (Thunderbird).
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.